Recombinant human growth hormone (r-hGH)

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Infant, Small for Gestational Age

Conditions

Infant, Small for Gestational Age

Trial Timeline

Feb 1, 2004 → Jul 1, 2009

NCT ID

NCT01067352

About Recombinant human growth hormone (r-hGH)

Recombinant human growth hormone (r-hGH) is a phase 3 stage product being developed by Merck for Infant, Small for Gestational Age. The current trial status is terminated. This product is registered under clinical trial identifier NCT01067352. Target conditions include Infant, Small for Gestational Age.

What happened to similar drugs?

4 of 13 similar drugs in Infant, Small for Gestational Age were approved

Approved (4) Terminated (3) Active (9)

✅Placebo + CisaprideJohnson & JohnsonApproved

✅alglucosidase alfa + alglucosidase alfaSanofiApproved

✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved

✅VigabatrinLundbeckApproved

🔄somatropinEli LillyPhase 3

🔄RotaTeq (V260) + IPVMerckPhase 3

🔄Genotropin (PN-180,307) Somatropin + Control-no treatmentPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01187550	Approved	Completed	Mar 1, 2007	Apr 1, 2009	Dwarfism, Pituitary
NCT01111019	Phase 2	Completed	Mar 21, 2006	Jan 17, 2017	Hypochondroplasia
NCT01067352	Phase 3	Terminated	Feb 1, 2004	Jul 1, 2009	Infant, Small for Gestational Age

Competing Products

20 competing products in Infant, Small for Gestational Age

See all competitors

Product	Company	Stage	Hype Score
SPIKEVAX	Moderna	Preclinical	0
TSHA-101	Taysha Gene Therapies	Phase 1/2	30
somatropin	Eli Lilly	Phase 3	40
Placebo + Cisapride	Johnson & Johnson	Approved	35
RotaTeq (V260) + IPV	Merck	Phase 3	40
recombinant somatropin	Merck	Pre-clinical	26
MAS825 + Placebo	Novartis	Phase 2	39
epoetin beta + epoetin beta	Roche	Pre-clinical	26
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
Prevenar (13v)	Pfizer	Pre-clinical	26
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV	Sanofi	Phase 3	40
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	35
Myozyme	Sanofi	Phase 2	35
Bacillus Clausii Multi ATB Resist + Placebo	Sanofi	Approved	43
Radiprodil	UCB	Phase 2	27
Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care	Bayer	Pre-clinical	23
Sabril®	Lundbeck	Pre-clinical	23
Vigabatrin	Lundbeck	Approved	32